Xifaxan rifaximin: Phase IIb data

In a double-blind Phase IIb trial in 680 patients, 2 weeks of twice-daily Xifaxan met the co-primary endpoints of significantly improved relief of bloating and diarrhea-associated IBS symptoms compare...